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Cyclosporine, everolimus, and tacrolimus are the corner-
stone of maintenance immunosuppressive therapy in renal 
transplantation. These drugs are characterized by a small 
therapeutic window and highly variable pharmacokinet-
ics (PK), which makes therapeutic drug monitoring (TDM) 
essential for maintaining adequate exposure and preventing 
serious drug-related toxicities.1–3
Cyclosporine, everolimus, and tacrolimus are primarily 
metabolized by cytochrome P450 enzymes, CYP3A4 and 
CYP3A5.4–7 Differences in activity of these metabolizing 
enzymes are likely to be responsible for a significant part 
of the interindividual variability in PK.8,9 Genetic polymor-
phisms in genes encoding these metabolizing enzymes 
have previously been found to explain a part of the variabil-
ity in PK of these immunosuppressive drugs.1,10–14 Recently, 
the decreased activity allele CYP3A4*22 was identified as 
a novel predictive marker for tacrolimus PK;15,16 however, 
these findings have not been successfully reproduced.11 
CYP3A4*22 has also been investigated to a less extent 
in cyclosporine PK, but its effect on everolimus PK is still 
unknown.15–17 CYP3A5*3 was studied before in relation to 
PK of everolimus, tacrolimus, and cyclosporine,10,18–20 but the 
CYP3A combined genotype (CYP3A4 and CYP3A5), which 
most likely better reflect CYP3A activity, has only been evalu-
ated for tacrolimus.15
The studies investigating the effect of CYP3A4*22 on 
tacrolimus PK were limited by the use of trough concentra-
tions and lack of data on comedications, and did not use 
population PK analysis. Such an approach enables to dif-
ferentiate between interpatient and intrapatient variability, 
which results in enhanced statistical power to identify fac-
tors influencing PK. Therefore, we investigated the effect of 
CYP3A4*22, CYP3A5*3, and CYP3A combined genotype on 




Cyclosporine. The cyclosporine data set consisted of 298 
adult renal transplant recipients, 187 men and 111 women. 
The majority of patients (88%) were of Caucasian origin. 
Mean age was 51 ± 13 years (range: 18–73 years) and mean 
weight was 77 ± 15 kg (range: 41–141 kg). A total of 6,800 
blood samples were collected.
Everolimus. A total of 97 adult renal transplant recipients, 62 
men and 35 women, were included. The majority of patients 
(86%) were of Caucasian origin. Mean age was 51 ± 13 years 
(range: 22–71 years) and mean weight was 79 ± 15 kg (range: 
50–129 kg). The data set consisted of 1,807 blood samples.
Tacrolimus. A total of 101 adult renal transplant recipients, 
56 men and 45 women, were included in this analysis. The 
majority of patients (77%) were of Caucasian origin. Mean 
age was 51 ± 14 years (range: 15–77 years) and mean weight 
was 76 ± 9 kg (range: 40–114 kg). The data set consisted of 
921 blood samples.
The concentration–time data were reviewed for complete-
ness and consistency of sampling and dosing times. All 
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Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive therapy in renal transplantation. These 
drugs are characterized by narrow therapeutic windows, highly variable pharmacokinetics (PK), and metabolism by CYP3A 
enzymes. Recently, the decreased activity allele, CYP3A4*22, was described as a potential predictive marker for CYP3A4 activity. 
This study investigated the effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and 
tacrolimus PK in renal transplant patients. CYP3A4*22 carriers showed a significant lower clearance for cyclosporine (−15%), 
and a trend was observed for everolimus (−7%) and tacrolimus (−16%). Patients carrying at least one CYP3A5*1 allele had 1.5-
fold higher tacrolimus clearance compared with noncarriers; however, CYP3A5*3 appeared to be nonpredictive for everolimus 
and cyclosporine. CYP3A combined genotype did not significantly improve prediction of clearance compared with CYP3A5*3 
or CYP3A4*22 alone. These data suggest that dose individualization of cyclosporine, everolimus, or tacrolimus therapy based 
on CYP3A4*22 is not indicated.
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measured concentrations were above the lower limit of quan-
tification. Baseline characteristics of the included patients are 
presented in Table 1.
Genotyping
The distributions of all single-nucleotide polymorphisms 
were in Hardy–Weinberg equilibrium. The distributions of the 
investigated CYP3A5 and CYP3A4 polymorphisms are listed 
in Table 2. Allele frequencies found in our data set corre-
sponded with those published previously.15,21,22 To investigate 
the combined effect of CYP3A4*22 and CYP3A5*3, geno-
type clusters were made as follows:
Slow metabolizers (C1): no CYP3A5 activity (CYP3A5*3/*3) 
and at least one decreased activity allele in CYP3A4 
(CYP3A4*22/*22 or CYP3A4*1/*22); intermediate metabo-
lizers group 1 (C2): no CYP3A5 activity (CYP3A5*3/*3) and 
no decreased activity allele in CYP3A4 (CYP3A4*1/*1); 
intermediate metabolizers group 2 (C3): carriers of at least 
one increased activity allele in CYP3A5 (CYP3A5*1/*1 or 
CYP3A5*1/*3) and at least one decreased activity allele in 
CYP3A4 (CYP3A4*22/*22 or CYP3A4*1/*22); and extensive 
metabolizers (C4): carriers of at least one increased activ-
ity allele in CYP3A5 (CYP3A5*1/*1 or CYP3A5*1/*3) and no 
decreased activity allele in CYP3A4 (CYP3A4*1/*1).
Table 1 Baseline characteristics of the patients included in the population PK/PG analyses
Cyclosporine Everolimus Tacrolimus
Male 187 62 56
Female 111 35 45
Age (years) 51 ± 13 51 ± 13 50 ± 14
Weight (kg) 77 ± 15 79 ± 15 76 ± 14
Body surface area (m2) 1.93 ± 0.22 1.94 ± 0.22 1.90 ± 0.22
Lean body mass (kg) 57 ± 10 58 ± 10 55 ± 10
Ideal BW (kg) 67 ± 9 67 ± 8 65 ± 9
Height (cm) 174 ± 10 174 ± 10 172 ± 11
Creatinine clearance (ml/min) 46 ± 30 70 ± 25 56 ± 35
Exposure
  Dose (mg) 177 ± 78 (50–500) 2.49 ± 0.79 (0.75–5.25) 4.2 ± 1.7 (0.5–12)
  AUC0–12 (µg·h/l) 5,648 ± 2,574 (702–16,499) 150 ± 42 (56–336) 170 ± 81 (49–462)
  Trough concentration 219 ± 131 (25–1,209) 9.3 ± 4.2 (2.6–32) 10.8 ± 5.5 (3.3–33.6)
Ethicity (%)
  Caucasian 88 86 77
  Mediterranean  3  5 13
  Asian  6  7  9
  Black  2  2  1
  Other  1
Hematocit (l/l) 0.36 ± 0.05 0.38 ± 0.04 0.34 ± 0.04
Underlying disease (n)
  Polycystic kidney disease 63 22 16
  Glomerulonephritis 50 15  7
  Diabetes mellitus 12  4 22
  Hypertension 50 15 15
  Focal segmental glomerulosclerosis 13  4  8
  E.c.i. 13  5  5
  Interstitial nephritis 11  3  3
  Urological 23 10  3
  Other 63 19 23
PK data
  Concentrations (µg/l) 591 ± 434 (25–2,615) 15.8 ± 8.1 (2.6–59) 16.8 ± 10 (3.3–96)
  Samples per patient 23 ± 6 (3–37) 19 ± 8 (7–36) 9 ± 2 (3–14)
  Total samples 6,800 1,807 921
AUC, area under the curve; BW, body weight; E.c.i., e causa ignota (cause unknown); PG, pharmacogenetic; PK, pharmacokinetic.
www.nature.com/psp




An overview of concomitant immunosuppressive and nonim-
munosuppressive medication with possible interaction of PK 
in the different groups is presented in Supplementary Table i.
Population PK modeling
The PK data of cyclosporine, everolimus, and tacrolimus were 
best described by a two-compartmental model with first-order 
absorption and first-order elimination from the central compart-
ment. The delayed absorption of everolimus and tacrolimus 
was best described with a lag time, and the delayed absorption 
of cyclosporine was best described with a transit compartment, 
using a first-order rate constant describing the transfer from 
the dose compartment into the transit compartment and sub-
sequently into the central compartment (Figure 1). Random-
effect parameters for interindividual variability in clearance 
(CL) and volume of central compartment (V
c
) were identified 
for all three drugs. Random-effect parameters for interindi-
vidual variability in the rate of absorption (K
a
) were identified 
for cyclosporine and everolimus. For tacrolimus, a random-
effect parameter for interindividual variability was identified 
for bioavailability. Variability between occasions (interoccasion 
variability) was best described with a random effect on (fixed) 
bioavailability (F) for cyclosporine, everolimus, and tacrolimus. 
For everolimus also interoccasion variability on K
a
 was identi-
fied. The random effects were tested for structural relationship 
with dose and time to create a model with unbiased and ran-
domly distributed random effects for covariate analysis.
The structural PK model of cyclosporine indicated an 
apparent clearance (CL/F) of 15.9 l/h, with the bioavailabil-
ity term fixed to 0.5, an apparent central distribution vol-
ume (V
c
/F) of 59.6 l, and an apparent peripheral distribution 
volume of 99.7 l. The absorption rate constant was 2.1 h−1. 
Intercompartmental clearance was 13.1 l/h. Interoccasion 
variability was estimated for the fixed bioavailability term and 
not for clearance because of a better model fit.
The structural PK model of everolimus indicated an appar-
ent clearance (CL/F) of 16.7 l/h, with the bioavailability term 
fixed to 1, an apparent central distribution volume (V
c
/F) of 
144 l, and an apparent peripheral distribution volume of 348 l. 
The absorption rate constant was 7.36 h−1. Intercompartmen-
tal clearance was 42.7 l/h, and lag time was 0.71 h. Interocca-
sion variability was estimated for the fixed bioavailability term 
and not for clearance because of a better model fit.
A dose–clearance relationship was observed showing an 
increase in apparent clearance with increasing dose accord-
ing to typical value of clearance (TVCL) = {[dose/2.5]*0.34}. This 
relationship improved the model fit in terms of objective func-
tion. The effect appeared to be caused by strict TDM. Patients 
with high everolimus blood levels (i.e., with a lower clear-
ance) were titrated to receive lower doses and vice versa to 
reach the stable target area under the curve (AUC)0−12h of 120 
µg·h/l. Subsequently, an apparent dose–clearance relation-
ship emerges. Additional tests described by Ahn et al.23 were 
performed, and it was confirmed that this effect was caused 
by strict TDM. Since two different assays were used for the 
determination of everolimus blood concentrations (liquid 
chromatography–tandem mass spectrometry and fluorescent 
polymerization immunoassay (FPIA)), a residual error for each 
assay was incorporated in the model. The model improved by 
adding an additive error to the FPIA data. This overestimation 
of FPIA was expected as investigated previously.24
The structural PK model of tacrolimus indicated an appar-
ent clearance (CL/F) of 5.7 l/h, with the bioavailability term 
Figure 1  Schematic representation of the linear two-compartment 
model with first-order absorption and elimination of cyclosporine, 




Table 2 Genotype distribution in study population
SnP Frequency and genotype
Cyclosporine (n = 298)
CYP3A4*22 (rs35599367) 264 *1/*1 32 *1/*22 2 *22/*22 — — 0 NG
CY
PA5*3 (rs776746)
239 *3/*3 48 *1/*3 9 *1/*1 — — 2 NG
CYP3A4/CYP3A5 cluster 29 C1 210 C2 5 C3 52 C4 2 NG
Everolimus (n = 97)
CYP3A4*22 (rs35599367) 87 *1/*1 8 *1/*22 1 *22/*22 — — 1 NG
CYP3A5*3 (rs776746) 81 *3/*3 12 *1/*3 3 *1/*1 — — 1 NG
CYP3A4/CYP3A5 cluster 9 C1 72 C2 0 C3 15 C4 1 NG
Tacrolimus (n = 101)
CYP3A4*22 (rs35599367) 92 *1/*1 7 *1/*22 2 *22/*22 — — 0 NG
CYP3A5*3 (rs776746) 79 *3/*3 18 *1/*3 4 *1/*1 — — 0 NG
CYP3A4/CYP3A5 cluster 7 C1 72 C2 2 C3 20 C4 0 NG
C1, CYP3A5*1 noncarriers and CYP3A4*22 carriers; C2, CYP3A5*1 noncarriers and CYP3A4*22 noncarriers; C3, CYP3A5*1 carriers and CYP3A4*22 carriers; 
C4, CYP3A5*1 carriers and CYP3A4*22 noncarriers; NG, not genotyped; SNP, single-nucleotide polymorphism.
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fixed to 0.23, an apparent central distribution volume (V
c
/F) 
of 20.5 l, and an apparent peripheral distribution volume of 
which was fixed to 500 l. The absorption rate constant was 
0.55 h−1. Intercompartmental clearance was 17.2 l/h, and lag 
time was 0.809 h. Interoccasion variability was estimated 
for the fixed bioavailability term. The PK data of cyclospo-
rine showed interindividual variability in CL/F of 23.5% and 
interoccasion variability (22.7%). Everolimus data revealed 
an interindividual variability in CL/F of 28.8% and interoc-
casion variability (26.4%). Tacrolimus showed considerably 
higher interindividual variability in CL/F of 42.2% and interoc-
casion variability (35.5%).
Covariate analysis
Pharmacogenetics. In Table 3, the summary of the uni-
variate pharmacogenetic covariate analysis is presented. 
CYP3A4*22 was significantly associated with cyclospo-
rine CL/F, and patients who carried at least one decreased 
activity allele in CYP3A4*22 had a 15% lower clearance 
compared with noncarriers. CYP3A combination showed a 
significant effect; C1, C2, and C3 showed lower clearance 
compared with C4 (−16, −2, and −12%, respectively). Evero-
limus PK did not reveal a significant relation with CYP3A5*3 
and CYP3A4*22, nor the CYP3A genotype combination. 
For tacrolimus, CYP3A5*3 was significantly associated with 
tacrolimus CL/F. Carriers of at least one CYP3A5*1 allele 
had 53% higher clearance compared with noncarriers. In 
contrast, CYP3A4*22 as covariate on CL/F did not result in 
a significant objective function drop (P = 0.218). Although 
not significant, a trend of 16% lower tacrolimus clearance 
was observed for CYP3A4*22 allele carriers. CYP3A com-
bination showed a significant effect on tacrolimus clearance. 
C1, C2, and C3 showed lower clearance compared with C4 
(−47, −33, and −3%, respectively). Although significant, the 
genetic covariates explained variability in clearance to a lim-
ited degree. In Figure 2, box plots of clearance vs. genotype 
are presented for cyclosporine, everolimus, and tacrolimus, 
and the figure also shows the significant variability within the 
genotype groups.
Demographics. The demographic covariates that showed 
a possible relation with the PK of the drugs in the diagnos-
tic plots were evaluated in the covariate analysis. Univari-
ate analysis (P < 0.05) on cyclosporine showed significant 
associations for the following demographic covariates: body 
weight (BW) on CL/F and V
c
/F, prednisolon dose ≥20 mg on 
K
a
 and F for cyclosporine, ideal BW on V
c
/F and hemato-
crit on CL/F for everolimus. Significant demographic covari-
ates for tacrolimus were prednisolone dose ≥25 mg on F and 
hematocrit on CL/F. The remaining demographic covariates 
such as ethnicity and other comedication that were evaluated 





Table 3 Summary of CYP3A4 and CYP3A5 covariate analysis




Var. (%) Mean value (%) 95% Ci (%)
Cyclosporine base model −6,750.443 23.5
  + CYP3A5*3 −6,751.429 0.986 0.32072 23.5 0 3 −2 to 8
  + CYP3A4*22 −6,767.684 17.241 0.00003 22.7 3.4 −14.5 −20 to −8
  + CYP3A combination −6,768.565 18.123 0.00041 22.7 3.4 C1 −16 −23 to −9
C2 −2 −7 to 3
C3 −12 −27 to 4
C4 0 −5 to 5
Everolimus base model 5,446.987 28.8
  + CYP3A5*3 5,444.175 2.059 0.15131 28.4 1.4 12 −0.3 to 24
  + CYP3A4*22 5,446.234 0.753 0.38553 28.7 0.3 −7 −23 to 9
  + CYP3A combination 5,443.734 3.253 0.19662 28.4 1.4 C1 −15 −29 to −1
C2 −10 −19 to −2
C3 NA NA
C4 0 −3 to 9
Tacrolimus base model 3,549.937 42.2
  + CYP3A5*3 3,530.215 19.722 0.00001 39.9 5.5 53 25 to 80
  + CYP3A4*22 3,548.418 1.519 0.21777 41.7 1.2 −16 −47 to 14
  + CYP3A combination 3,527.993 21.717 0.00007 36.6 13.3 C1 −47 −69 to −24
C2 −33 −46 to −20
C3 −3 −48 to 41
C4 0 −18 to 18
ΔOF, Δ objective function; C1, CYP3A5*1 noncarriers and CYP3A4*22 carriers; C2, CYP3A5*1 noncarriers and CYP3A4*22 noncarriers; C3, CYP3A5*1  carriers 
and CYP3A4*22 carriers; C4, CYP3A5*1 carriers and CYP3A4*22 noncarriers; Expl. Var. (%), explained variability in percentage of total; MVOF, minimal value 
of objective function; NA, not applicable; P value, χ2 distribution P value; RSE, relative standard error; Var. CL (%), remaining variability in clearance.
Mean value (%) represents the difference in CL/F compared with the reference group, which is 0.
www.nature.com/psp
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Figure 2  Box plots representing the average cyclosporine, everolimus, and tacrolimus apparent clearance (l/h) of the different genotype 
groups with error bars and the number of patients in each group. CYP3A4 (*1/*1 = CYP3A4*22 noncarriers, *1/*22 or *22/*22 = CYP3A4*22 
carriers, NG = not genotyped), CYP3A5 (*1/*3 or *1/*1 = CYP3A5*1 carriers, *3/*3 = CYP3A5*1 noncarriers, NG = not genotyped), and CYP3A 
cluster: (C1: CYP3A5*3/*3 and CYP3A4*22/*22 or CYP3A4*1/*22, C2: CYP3A5*3/*3 and CYP3A4*1/*1, C3: CYP3A5*1/*1 or CYP3A5*1/*3 
and CYP3A4*22/*22 or CYP3A4*1/*22, and C4: CYP3A5*1/*1 or CYP3A5*1/*3 and CYP3A4*1/*1, NG = not genotyped). *P < 0.01. Apparent 
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After the forward inclusion and backward elimination step, 
the following covariates remained significant (P < 0.01):
Cyclosporine: BW on CL/F and V
c
/F, prednisolon dose 
≥20 mg on K
a
 and F (better model fit and objective func-
tion drop compared with prednisolon dose on CL/F), and 
CYP3A4*22 on CL/F. Interindividual variability of CL/F 
decreased from 23.5 to 22.6%. In Supplementary Table ii, 
all significant covariates improving model fit together with 
their effects on observed variability are presented for cyclo-
sporine, everolimus, and tacrolimus. Everolimus: ideal BW 
centered on the population median as exponential function 
on V
c
/F improved the model, reducing the random variability 
between individuals in V
c
/F by 12%. Hematocrit was lost in 
the forward elimination step (P > 0.01) and was, therefore, 
not incorporated in the final model. Significant covariates for 
tacrolimus were found in prednisolone dose ≥25 on F (higher 
objective function drop compared with prednisolon dose on 
CL/F), CYP3A5*3 and hematocrit on tacrolimus CL/F. Incor-
poration of these covariates decreased the interindividual 
variability of CL/F from 42.2 to 39.1%, and the interoccasion 
variability was reduced from 35.5 to 29.3%.
The population PK parameters obtained with the base 
and final models are presented in Table 4 (Supplementary 
Models 1-3). Evaluation of the precision of the PK param-
eters of all three models was performed with 1,000 bootstrap 
replications. The percentage of successful runs was 99% for 
cyclosporine, 82% for everolimus, and 96% for tacrolimus. 
Moreover, the parameter estimates of the nonsuccessful 
runs were analyzed and did not deviate from the parameter 
estimates of the successful runs. The mean values for all 
fixed-effect parameters were within 15% of those obtained 
by the final model, indicating good reliability. Since different 
dosages were used during the study, the performance of 
the model was evaluated with a prediction-corrected visual 
predictive check (VPC).25 Predictive and observed intervals 
(10%, 90%, and median) are almost identical showing good 
predictive performance of the final models (Figure 3).
DiSCUSSiOn
This is the first comprehensive study investigating the influ-
ence of CYP3A4*22 and CYP3A5*3 variant alleles and 
its combined clusters on the PK of the three main kidney 
transplant immunosuppressive drugs cyclosporine, evero-
limus, and tacrolimus. This study demonstrates that car-
riership of the CYP3A4*22 allele is significantly associated 
with a decreased cyclosporine clearance. Carriers of the 
CYP3A4*22 allele showed 15% lower cyclosporine clear-
ance as compared with noncarriers. Moreover, CYP3A geno-
type clusters were significantly associated with cyclosporine 
and tacrolimus clearance but not with everolimus clearance. 
Finally, this study also demonstrates that patients carrying 
at least one CYP3A5*1 allele have on average 53% higher 
tacrolimus clearance compared with noncarriers.
Cyclosporine, everolimus, and tacrolimus are primarily 
eliminated by CYP3A enzymes,4–6,26 and as shown before in in 
vitro and in vivo studies, CYP3A4 is involved in their PK.5,27,28 
CYP3A4 is most likely predominant in cyclosporine and 
everolimus metabolic clearance, and CYP3A5 contributes 
more significantly to tacrolimus metabolic clearance com-
pared with CYP3A4.5,6 In contrast to CYP3A5, CYP3A4 
lacked a reliable genetic marker for prediction of CYP3A4 
expression, which was suitable for dosing  adjustments;29 
however, CYP3A4*22 was recently marked as a potential 
reliable marker.15,16 In contrast, as part of our analysis, only 
a significant influence of CYP3A4*22 on cyclosporine PK 
was found, but a trend was also seen in tacrolimus (16% 
lower clearance (95% confidence interval: −47 to 14%)) 
and everolimus PK (7% lower clearance (95% confidence 
interval: −23 to 9%)). This effect is not high enough to justify 
dose modification based on CYP3A4*22. In clinical practice, 
only an effect of at least 20% on clearance will lead to dose 
adjustments, since these drugs also possess a considerable 
degree of intraindividual variability. Since the clinical studies 
from which all data were derived were not primarily designed 
to identify a genotype effect and the fact that we found no 
clinically relevant genotype effect for CYP3A4*22, we had to 
confirm afterwards that our study had enough power. There-
fore, we performed a posterior power calculation using the 
stochastic simulation and estimation tool of the PsN toolkit to 
determine the power (95 and 99% confidence) of our study 
to find a clinically relevant genotype effect (at least 20%) on 
cyclosporine, everolimus, and tacrolimus PK.30,31 With the 
most unfavorable genotype distribution (CYP3A4*22) and 
the least amount of data (tacrolimus), we found a power of 
95% (α = 0.01) and 91% (α = 0.01) in detecting a clinically 
relevant genotype (at least 20%) effect. It is therefore highly 
unlikely that our analysis was underpowered and missed a 
clinically relevant effect of the investigated genotypes due to 
limited sample size.
In contrast to our findings, the studies of Elens et al.15,32 
and Gijsen et al.16 showed that CYP4A4*22 allele carriers 
required up to 30% lower tacrolimus doses compared with 
CYP3A4*1/*1 to reach target trough concentration. How-
ever, these exploratory findings have not been confirmed by 
another research group. Moreover, more recently, Santoro 
et al.11 presented a study in 140 renal transplant patients 
showing that independent effects of CYP3A4*22 on tacro-
limus dose requirements could not be verified. The studies 
of Elens et al.15,32 had some limitations such that the data 
were not corrected for corticosteroid use or hematocrit levels. 
Corticosteroid and hematocrit levels are known to influence 
tacrolimus exposure12,33 and could therefore have influenced 
their results. The study of Gijsen et al.16 performed on a small 
data set had the limitation that they could not correct their 
results for comedication. Both studies15,16 only used trough 
levels in their analysis, which do not give a full insight in PK. 
The more recent study of Elens et al.32, in contrast, used an 
additional 59 whole PK curves to support their conclusion; 
however, since they were collected only on one occasion, 
intraindividual variability could not be assessed. To investi-
gate whether shrinkage could have been the cause of the 
lack of significance of the CYP3A4*22 effect in this study, 
we also performed the univariate genetic covariate analy-
sis with only the first PK profiles to be able to compare the 
results in more details with Elens et al. (see Supplementary 
Table iii). The results were the same as with the complete 
data set, so therefore, the results found in the study of Elens 
et al.32 could not be replicated in our study. In another study 
www.nature.com/psp
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Table 4 Summary of model parameter estimates cyclosporine, everolimus, and tacrolimus
PK parameter
Base model Final model 1,000 bootstrap runs






  CL/F 15.9 2 — 15.6 1.8 — — 15.6 15.1 to 16.1
    BW on CL/F — — — 0.3 32.7 — 2 0.3 0.09 to 0.48
    CYP3A4*22 on CL/F — — — −0.15 21 — 4 −0.15 −0.20 to −0.08
  F (fixed) 0.5 — — 0.5 — — — 0.5 —
    DDPR ≥20 mg — — — −0.12 17.3 — 4 −0.12 −0.15 to −0.08
  V
c
/F (l) 59.6 4 — 56 5 — — 55.8 50.3 to 61.2
    BW on V
c
/F — — — 0.61 36 — 7.5 0.61 0.16 to 1.04
    Q/F (l/h) 13.1 5 — 13 7 — — 13 11.5 to 15.3
    Vp/F (l) 99.7 8 — 90.4 9 — — 90.5 80.2 to 110.7
    K
a
 (h−1) 2.1 6 — 2.16 9 — 2.2 1.9 to 2.5
    DDPR ≥20 mg — — — −0.45 11 — 2.5 −0.45 −0.53 to −0.34
  IIV
    IIV CL/F (CV%) 23.5 8 10 22.6 9.6 10 — 22.2 18.5 to 26.7
    IIV V
c
/F (CV%) 41.5 8 19 42.3 10.4 19 — 42.1 32.8 to 50.8
    IIV K
a
 (CV%) 48.6 9 21 49 10.6 23 — 49.1 38.5 to 59.0
  IOV
    IOV F (CV%) 22.7 7 26 21.7 9 29 — 21.7 18.4 to 25.0
  Random residual variability
    σ1 (additive error) 0.301 6 10 0.297 12.6 10 — 0.293 0.268 to 0.335
Everolimus
  CL/F 16.7 4 — 16.7 4 — — 16.7 15.4 to 17.8
  F (fixed) 1 — — 1 — — — 1 —
  V
c
/F (l) 144 5 — 140 5 — — 143 131 to 156
  IBW on Vc/F — — — −0.96 28 — 12 −0.95 −1.55 to −0.39
  Q/F (l/h) 42.7 6 — 43.1 6 — — 43.4 38.7 to 49.5
  Vp/F (l) 348 22 — 343 20 — — 336 247 to 585
  K
a
 (h−1) 7.3 20 — 7 16.3 — — 7.1 4.7 to 11.1
  Lagtime 0.71 3 — 0.71 3 — — 0.71 0.65 to 0.74
  Dose CL/F (TDM effect) 0.34 31 — 0.34 28 — — 0.35 0.16 to 0.49
  IIV
    IIV CL/F (CV%) 28.8 48 9 28.9 13 9 — 28.7 21.7 to 34.6
    IIV V
c
/F (CV%) 35.1 26 12 30.6 10 14 — 30.4 25.3 to 37.0
    IIV K
a
 (CV%) 115.8 16 35 111 13 35 — 108.1 84.9 to 136.9
  IOV
    IOV K
a
 (CV%) 127.3 11 39 127.3 11 38 — 127.3 102.0 to 160.9
    IOV F (CV%) 26.4 6 7 26.3 5.7 6 — 26.2 23.3 to 29.5
  Random residual variability
    σ1 (proportional error) LCMS 14.5 7.7 16 14.5 7.6 15 — 14.3 11.8 to 16.7
    σ2 (proportional error) FPIA 6.6 14.3 15 6.6 14.1 15 — 6.7 4.1 to 8.2
    σ3 (additive error) FPIA 1.06 14 15 1.06 14 15 — 1.08 0.8 to 1.44
Table 4 Continued on next page
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by Elens et al.,17 no significant effect was found for cyclospo-
rine trough concentrations and CYP3A4*22 carriership. Our 
analysis was based on an extensive amount of data consist-
ing of AUCs. Moreover, a wide range of factors possibly influ-
encing PK, including demographic factors and comedication, 
was also investigated.
The difference in tacrolimus clearance between CYP3A5*1 
carriers and noncarriers found in the current analysis was sim-
ilar to what was published previously.10,12 We confirmed with 
our study that dosing adjustments based on CYP3A5*3 could 
be indicated to quickly reach target exposure; however, the 
variability explained by CYP3A5*3 is limited, and the variabil-
ity within the CYP3A5 genotype groups remains significant, 
and therefore, close TDM remains essential. The absence of 
a clinically relevant influence of CYP3A5*3 on cyclosporine 
and everolimus PK is in line with previous studies.29,34,35
Using CYP3A combined genotype of CYP3A4 and 
CYP3A5 as a predictor for cyclosporine, everolimus, or 
tacrolimus clearance does not seem to be an improvement 
compared with the individual polymorphisms. As shown in 
the results, the combined analysis did not further improve 
identification groups of slow metabolizers, intermediate 
metabolizers, and extensive metabolizers. For cyclosporine, 
the differences in average clearance between the groups 
remain less than 16%. For tacrolimus, a difference of 14% 
is introduced for noncarriers of the CYP3A5*1 allele by the 
effect of CYP3A4*22 carriership, which makes a further dif-
ferentiation unnecessary.
Up to now, the only suggested clinically relevant polymor-
phisms in CYP3A enzymes relevant for kidney transplan-
tation are CYP3A5*3 and CYP3A5*6 for tacrolimus, which 
are primarily found in Africans and have low allelic frequen-
cies in the Caucasian population. CYP3A5*6 was left out 
of this analysis because of too low allele frequency (<6%). 
CYP3A4*22 is able to predict CYP3A4 activity; however, the 
clinical relevancy seems to be limited. The search for a reli-
able and clinically relevant predictive biomarker for CYP3A4 
is still open, although CYP3A4 phenotyping shows more 
promising results as recently published by de Jonge et al.14
The demographic covariates that were identified in this 
study have been reported in previous studies.10,19,36,37 The 
clinical relevancy of the different identified covariates is lim-
ited since the explained variability by the individual covari-
ates did not exceed 12%. The effect of prednisolone dose 
on cyclosporine and tacrolimus bioavailability (high dose, 
lower bioavailability) can be explained by CYP3A induction 
in the intestine and has been reported before.10,37,38 The cut-
off values were chosen based on literature10,37,38 and highest 
objective function drop. The PK parameter estimates of the 
three models were in agreement with those found in previous 
Tacrolimus
  CL/F 5.7 5 — 6.27 6 — — 6.27 5.59 to 7.01
    CYP3A5*3 on CL/F — — — 0.52 26 — 5.5 0.52 0.25 to 0.82
    HTC on CL/F + IOV F — — — −0.587 35 — 3/8 −0.56 −0.96 to −0.23
  F (fixed) 0.23 — — 0.23 — — — 0.23 —
    DDPR ≤25 mg (IOV F) — — — 0.314 27 — 12.4 0.32 0.15 to 0.49
    V
c
/F (l) 20.5 22 — 25.5 20 — — 25.2 16.4 to 38.5
    Q/F (l/h) 17.2 9 — 21 11 — — 21 17 to 25.4
    Vp/F (l) (fixed) 500 — — 500 — — — 500 —
    K
a
 (h−1) 0.55 10 — 0.55 8 — — 0.55 0.47 to 0.69
    Lagtime 0.81 7 — 0.81 7 — — 0.81 0.67 to 0.91
  IIV
    IIV CL/F (CV%) 42.2 15 26 39.1 16 27 — 38.5 25.9 to 50.3
    IIV V
c
/F (CV%) 124.1 13 18 124.9 14 18 — 125.8 95.7 to 162.5
    IIV F (CV%) 38.1 21 39 39.2 17 35 — 39 23.1 to 51.6
  IOV
    IOV F (CV%) 35.5 12 26 29.3 14 25 — 28.8 21.1 to 36.2
  Random residual variability
    σ1 (proportional error) 17.3 5 16 17.4 5 16 — 17.3 15.7 to 19.0
CI, confidence interval; CL, clearance; CYP, cytochrome P450; DDPR, daily dose prednisolon; Expl. Var. (%), percentage explained of total variability; F, bioavail-
ability; FPIA, fluorescence polarization immunoassay; HTC, hematocrit; IBW, ideal body weight; IIV, interindividual variability; IOV, interoccasion variability; K
a
, 
absorption rate constant; Lagtime, lagtime of absorption; LCMS, liquid chromatography/tandem mass spectrometry; Q, intercompartmental clearance; Shr. (%), 
shrinkage (%); TDM, therapeutic drug monitoring; V
c
, distribution volume of the central compartment; Vp, distribution volume of the peripheral compartment.
Table 4 Continued
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studies,19,36,39 when taking the effect of differences in fixed 
bioavailability terms, patient population, and TDM assays into 
account. In contrast to a number of other studies, we fixed the 
bioavailability term to 0.5 for cyclosporine and 0.23 for tacroli-
mus instead of 1, which leads to an apparent clearance twice 
lower for cyclosporine and 4.3 times lower for tacrolimus. The 
variability in PK was high in tacrolimus, although as known 
from literature,1 around 20% of this could be explained by the 
fact that the majority of the data used in the current analysis 
were collected within 2 weeks after transplantation. Unstable 
renal transplant patients show much higher variability in PK.1
Cyclosporine absorption was best described with a transit 
compartment as we previously described.37 As found in our 
smaller study, ideal BW significantly correlates with V
c
/F of 
everolimus.19 Since everolimus is primarily partitioned into red 
blood cells and 75% of the plasma fraction is bound to plasma 
proteins, this relationship can be physiologically explained 
since length and sex are incorporated in the ideal weight 
formula.2,40 The significant effect of hematocrit on everolimus 
clearance in the univariate covariate analysis could also be 
explained by the same mechanism. Ethnicity could not be 
identified as a covariate on clearance of everolimus or cyclo-
sporine as was found previously by Kovarik et al.41 and Hes-
selink et al.36 This difference could be explained by the lack of 
black patients in our cohort. Although theoretically plausible, 
we did not find an effect of concomitant medication such as 
statins, calcium antagonists, sulfamethoxazole/trimethoprim, 
or proton pump inhibitors on CL/F. This is in accordance with 
what has previously been described in literature.8,41 Comedi-
cations known to have a potent effect on the PK of the drugs 
were avoided for safety reasons.42 The remaining variability 
in clearance between patients of our final model was 22.6% 
for cyclosporine, 28.8% for everolimus, and 38.9% for tacroli-
mus, which could reflect the wide interindividual variability in 
CYP3A4 expression.43
Our study has some limitations: fatty food intake, nonad-
herence, or diarrhea could not be quantified, although these 
factors could contribute to the observed variability since pre-
viously published studies reported food interactions with the 
investigated drugs.8,9,44 Furthermore, K
a
 of everolimus was 
difficult to estimate since the data set had low number of 
blood samples collected between 0 and 1 h after dose intake, 
but is unlikely that this would have influenced the genotype 
covariate analysis on clearance.
In conclusion, CYP3A4*22 does not influence cyclosporine, 
everolimus, or tacrolimus PK to a clinically relevant extent. This 
study confirmed that CYP3A5*3 is only suitable as a predic-
tive marker for tacrolimus clearance, but close TDM remains 
essential due to the remaining variability between patients with 
the same genotype. The CYP3A4 and CYP3A5 combined gen-
otypes do not further improve the predictive performance com-
pared with the predictive performance of the polymorphisms 
alone. Therefore, the newly discovered CYP3A4*22 or CYP3A 
combined genotypes are not indicative to be used for dose 
adjustments in clinical practice to further improve immunosup-
pressive therapy of cyclosporine, tacrolimus, or everolimus in 
the investigated patient population.
METHODS
Cyclosporine 
Clinical data from 298 renal transplant recipients treated with 
a immunosuppressive regimen cyclosporine (Neoral, Novartis, 
Basel, Switzerland), prednisolone, and mycophenolate sodium 
participating in a run in phase of a prospective, open, random-
ized, multicenter study were studied up to 6 months after trans-
plantation.42 Induction therapy consisted of two doses of 20 mg 
basiliximab (Simulect Novartis, Basel, Switzerland) before 
transplantation and on day 4, rapidly tapered prednisolone 
dose (50 mg twice daily (b.i.d.) intravenously tapered to daily 
10 mg oral prednisolone). Cyclosporine therapy was started at 
an oral dose of 4 mg/kg b.i.d. and was supported by routine 
TDM based on AUC0–12 h. TDM was aimed at a target of 5,400 
µg·h/l the first 6 weeks and 3,250 µg·h/l thereafter. Cyclospo-
rine concentrations were obtained at steady state at clinical 
visits, which were scheduled at 1, 5, 12, and 24 weeks after 
transplantation.
Everolimus 
Clinical data from 97 stable renal transplant recipients treated 
with immunosuppressive duotherapy consisting of everolimus 
(Certican, Novartis) and prednisolone, participating in a pro-
spective, open, randomized, multicenter study were studied 
Figure 3 Prediction-corrected visual predictive checks with 80% prediction interval of cyclosporine, everolimus, and tacrolimus. The observed 
concentrations are shown as solid circles. The solid lines with open circles represent the observation intervals. The solid lines represent the 
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from 6 to 24 months after transplantation.42 During the first 6 
months, patients were treated with an immunosuppressive reg-
imen cyclosporine, prednisolone, and mycophenolate; thereaf-
ter, a scheduled biopsy was performed. Patients whose biopsy 
showed no sign of rejection were included. Subsequently, 
cyclosporine and mycophenolate were discontinued. Evero-
limus therapy was started at an oral dose of 3 mg b.i.d. and 
was supported by routine TDM based on AUC0–12 h. TDM was 
aimed at a target of 120 µg·h/l. Everolimus concentrations were 
obtained at steady state at regular clinical visits scheduled at 
32, 52, 78, and 104 weeks after transplantation.
Tacrolimus
Clinical data from 101 renal transplant patients on an immu-
nosuppressive regimen of tacrolimus (Prograft, Astellas, 
Leiden, The Netherlands), prednisolone, and mycopheno-
late mofetil were studied for first two TDM moments after 
transplantation. Induction therapy consisted of two doses of 
20 mg basiliximab (Simulect) before transplantation and, on 
day 4, rapidly tapered prednisolone dose (50 mg b.i.d. intra-
venously tapered to daily 10 mg oral prednisolone). Tacroli-
mus therapy was started at a fixed oral dose of 5 mg b.i.d. 
and was supported by routine TDM based on AUC0–12 h. 
TDM was aimed at a target of 160 µg·h/l the first 6 weeks 
and 120 µg·h/l thereafter. Tacrolimus concentrations were 
obtained at steady state from 1 to 66 weeks after transplan-
tation with a median of 2 weeks.
The study was approved by the Medical Ethics Committee 
of Leiden University Medical Center, and patients gave writ-
ten informed consent.
Bioanalytics
TDM was performed on the basis of Bayesian estimation 
(cyclosporine45 and tacrolimus46) or trapezoidal rule (evero-
limus) (blood concentration at t = 0, 1, 2, 3, 4, 5, and 6 h 
(everolimus and tacrolimus) up to 12 h for some patients 
(cyclosporine) or t = 0, 1, 2, 3, 4 h (in a small number of visits 
in the everolimus data set)) using MW/Pharm 3.5 (Mediware, 
Groningen, The Netherlands).47 TDM samples were deter-
mined in whole blood by a validated liquid chromatography-
mass spectrometric method in two laboratories24,48 or by 
FPIA (Abbott Laboratories, Abbott Park, IL). Tacrolimus blood 
concentrations were all determined with liquid chromatogra-
phy–mass spectrometry/tandem mass spectrometry, everoli-
mus with liquid chromatography–mass spectrometry/tandem 
mass spectrometry and FPIA, and cyclosporine with FPIA 
alone. Table 1 shows the samples distribution of the blood 
concentrations used in this study.
Genotyping assays
DNA was isolated from blood from ethylene diamine tetraacetic 
acid blood collection tubes collected from patients. CYP3A4*22 
was determined with TaqMan 7500 (Applied Biosystems, 
Nieuwerkerk a.d. IJssel, The Netherlands) with predesigned 
assays, according to the manufacturers’ protocol. CYP3A5*3 
was determined with Pyrosequencer 96MA (Isogen, IJssel-
stein, The Netherlands). Further details with regard to the 
genotyping protocol are provided in Supplementary Table iV. 
No inconsistencies were observed. All allele frequencies were 
in Hardy–Weinberg equilibrium.
PK modeling
Nonlinear mixed effect modeling was used to estimate PK 
parameters from blood concentration–time data. NONMEM 
(v7.2.1, Icon Development Solutions, Ellicott City, MD) was 
used for modeling, using PsN toolkit 3.4.2 and Piranã ver-
sion 2.8.0 (ref. 49) as modeling environment. Results were 
analyzed using statistical software package R (v2.15.2) and 
RStudio (v0.97.248; Boston, MA). First-order conditional 
estimation method with interaction was used throughout 
the analysis. Model selection was based on statistical sig-
nificance, goodness of fit, and stability. Throughout the model 
building process, an altered model was chosen over a pre-
cursor model if the difference in the objective functions (−2 
log likelihood) was >6.63 (P < 0.01, with 1 degree of freedom, 
assuming χ2 distribution) .
Base model 
The model was initially developed strictly PK without covari-
ates. Since only data after oral and not after intravenous 
administration were available, the absolute oral bioavailability 
could not be determined. Therefore, the value for bioavail-
ability was fixed. Plots of observed concentration–time data 
were examined. One- and two-compartmental PK models 
with first-order elimination were compared to find the best fit 
of the concentration–time data. The use of transit compart-
ments and a lag time for drug absorption were explored. After 
building the base model, demographic and genetic covari-
ates were explored.
Covariate analysis 
Diagnostic plots were constructed of the random effects of 
clearance, volume, K
a
, and F vs. the demographic (age, BW, 
sex, ethnicity, length, lean BW, ideal BW, body surface area 
(BSA), BMI (formulas in Supplementary Table V), hemato-
crit, underlying disease, and comedications (also weighted 
residuals vs. comedication plots)) and pharmacogenetic 
(CYP3A4*22 and CYP3A5*3) characteristics. Polymor-
phisms were selected based on theoretical relationship and 
minimal allele frequency (>6%) to assure detection of clini-
cally relevant effect on PK. Based on these diagnostic plots, 
further testing in the pharmacostatistical model was per-
formed. Subsequently, selected covariate relationships were 
evaluated by forward inclusion and backward deletion proce-
dure. A covariate effect was only maintained in the model, if 
the inclusion resulted in a reduction in random variability and 
improved model fit.
VPC with prediction correction
Performance of candidate and final models for cyclosporine, 
everolimus, and tacrolimus PK models was evaluated using 
prediction-corrected VPCs, by simulation of 500 simulated 
data sets. A prediction-corrected VPC differs from a tradi-
tional VPC in that both observations and the model predic-
tions are normalized for the typical model prediction in each 
bin of independent variables.50
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